HEPION PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Basic
HEPION PHARMACEUTICALS, INC. (HEPA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$48.93 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-16.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-04-16
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$9.73M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$9.27M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was -$7.67M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-03-31 was -$6.06M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$48.93M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$45.34M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$32.72M.
- HEPION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$20.36M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 2 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 5 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 8 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 11 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | -$48.93M 10-K · filed 2024-04-16 | ||||||||
| 2022-12-31 | -$45.34M 10-K · filed 2024-04-16 | ||||||||
| 2021-12-31 | -$9.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-10 | -$18.99M derived: sum of 2 quarters · filed 2023-04-10 | -$26.66M derived: sum of 3 quarters · filed 2023-04-10 | -$32.72M 10-K · filed 2023-04-10 | |||||
| 2021-09-30 | -$9.27M 10-Q · filed 2021-11-15 | -$16.93M derived: sum of 2 quarters · filed 2021-11-15 | -$23.00M 10-Q · filed 2021-11-15 | -$27.95M derived: sum of 4 quarters · filed 2022-04-08 | |||||
| 2021-06-30 | -$7.67M 10-Q · filed 2021-08-16 | -$13.73M 10-Q · filed 2021-08-16 | -$18.68M derived: sum of 3 quarters · filed 2022-04-08 | -$24.92M derived: sum of 4 quarters · filed 2022-04-08 | |||||
| 2021-03-31 | -$6.06M 10-Q · filed 2021-05-14 | -$11.02M derived: sum of 2 quarters · filed 2022-04-08 | -$17.26M derived: sum of 3 quarters · filed 2022-04-08 | -$22.20M derived: sum of 4 quarters · filed 2022-04-08 | |||||
| 2020-12-31 | -$4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08 | -$11.19M derived: sum of 2 quarters · filed 2022-04-08 | -$16.13M derived: sum of 3 quarters · filed 2022-04-08 | -$20.36M 10-K · filed 2022-04-08 | |||||
| 2020-09-30 | -$6.24M 10-Q · filed 2021-11-15 | -$11.18M derived: sum of 2 quarters · filed 2021-11-15 | -$15.40M 10-Q · filed 2021-11-15 | -$17.61M derived: sum of 4 quarters · filed 2021-11-15 | |||||
| 2020-06-30 | -$4.94M 10-Q · filed 2021-08-16 | -$9.17M 10-Q · filed 2021-08-16 | -$11.38M derived: sum of 3 quarters · filed 2021-08-16 | -$13.21M derived: sum of 4 quarters · filed 2021-08-16 | |||||
| 2020-03-31 | -$4.23M 10-Q · filed 2021-05-14 | -$6.44M derived: sum of 2 quarters · filed 2021-05-14 | -$8.27M derived: sum of 3 quarters · filed 2021-05-14 | -$14.70M derived: sum of 4 quarters · filed 2021-05-14 | |||||
| 2019-12-31 | -$2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$4.04M derived: sum of 2 quarters · filed 2021-03-31 | -$10.47M derived: sum of 3 quarters · filed 2021-03-31 | -$12.48M 10-K · filed 2021-03-31 | -$12.16M 10-K · filed 2020-05-14 | ||||
| 2019-09-30 | -$1.83M 10-Q · filed 2020-11-16 | -$8.26M derived: sum of 2 quarters · filed 2020-11-16 | -$10.27M 10-Q · filed 2020-11-16 | -$12.49M derived: sum of 4 quarters · filed 2020-11-16 | |||||
| 2019-06-30 | -$6.43M 10-Q · filed 2020-08-12 | -$8.44M 10-Q · filed 2020-08-12 | -$10.66M derived: sum of 3 quarters · filed 2020-08-12 | -$19.62M derived: sum of 4 quarters · filed 2020-08-12 | |||||
| 2019-03-31 | -$2.01M 10-Q · filed 2020-06-29 | -$4.23M derived: sum of 2 quarters · filed 2020-06-29 | -$13.19M derived: sum of 3 quarters · filed 2020-06-29 | -$17.22M derived: sum of 4 quarters · filed 2020-06-29 | |||||
| 2018-12-31 | -$2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-14 | -$11.18M derived: sum of 2 quarters · filed 2020-05-14 | -$15.21M derived: sum of 3 quarters · filed 2020-05-14 | -$17.90M 10-K · filed 2020-05-14 | |||||
| 2018-09-30 | -$8.96M 10-Q · filed 2019-11-14 | -$12.99M derived: sum of 2 quarters · filed 2019-11-14 | -$15.68M 10-Q · filed 2019-11-14 | -$17.42M derived: sum of 4 quarters · filed 2019-11-14 | |||||
| 2018-06-30 | -$4.03M 10-Q · filed 2019-08-14 | -$6.72M 10-Q · filed 2019-08-14 | -$8.46M derived: sum of 3 quarters · filed 2019-08-14 | -$14.23M derived: sum of 4 quarters · filed 2019-08-14 | |||||
| 2018-03-31 | -$2.69M 10-Q · filed 2019-05-15 | -$4.43M derived: sum of 2 quarters · filed 2019-05-15 | -$10.20M derived: sum of 3 quarters · filed 2019-05-15 | -$8.15M derived: sum of 4 quarters · filed 2019-05-15 | |||||
| 2017-12-31 | -$1.74M derived: 10-K 6 month − 10-Q 3 month · filed 2019-03-14 | -$7.51M 10-K · filed 2019-03-14 | -$5.46M derived: sum of 3 quarters · filed 2019-03-14 | -$13.08M 10-K · filed 2019-03-14 | |||||
| 2017-09-30 | -$5.77M 10-Q · filed 2018-11-14 | -$3.72M derived: sum of 2 quarters · filed 2018-11-14 | -$11.34M 10-Q · filed 2018-11-14 | -$15.85M derived: sum of 4 quarters · filed 2018-11-14 | |||||
| 2017-06-30 | $2.05M 10-Q · filed 2018-08-14 | -$5.57M 10-Q · filed 2018-08-14 | -$10.07M derived: sum of 3 quarters · filed 2018-08-14 | -$14.89M 10-K · filed 2019-03-14 | |||||
| 2017-03-31 | -$7.62M 10-Q · filed 2018-05-15 | -$12.12M derived: sum of 2 quarters · filed 2018-05-15 | -$16.94M 10-Q · filed 2017-04-12 | ||||||
| 2016-12-31 | -$4.51M 10-Q · filed 2017-02-14 | -$9.32M 10-KT · filed 2018-03-26 | |||||||
| 2016-06-30 | -$5.21M derived: 10-KT 12 month − 10-Q 9 month · filed 2018-03-26 | -$9.12M derived: sum of 2 quarters · filed 2018-03-26 | -$12.15M derived: sum of 3 quarters · filed 2018-03-26 | -$17.00M 10-KT · filed 2018-03-26 | |||||
| 2016-03-31 | -$3.92M 10-Q · filed 2017-04-12 | -$6.95M derived: sum of 2 quarters · filed 2017-04-12 | -$11.79M 10-Q · filed 2017-04-12 | ||||||
| 2015-12-31 | -$3.03M 10-Q · filed 2017-02-14 | -$7.87M 10-Q · filed 2017-02-14 | |||||||
| 2015-06-30 | -$5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-28 | -$12.77M derived: sum of 2 quarters · filed 2016-09-28 | -$20.72M derived: sum of 3 quarters · filed 2016-09-28 | -$22.19M 10-K · filed 2016-09-28 | |||||
| 2015-03-31 | -$7.40M 10-Q · filed 2016-05-13 | -$15.35M derived: sum of 2 quarters · filed 2016-05-13 | -$16.82M 10-Q · filed 2016-05-13 | -$12.44M derived: sum of 4 quarters · filed 2016-05-13 | |||||
| 2014-12-31 | -$7.95M 10-Q · filed 2016-02-12 | -$9.42M 10-Q · filed 2016-02-12 | -$5.04M derived: sum of 3 quarters · filed 2016-02-12 | -$14.35M derived: sum of 4 quarters · filed 2016-02-12 | |||||
| 2014-09-30 | -$1.47M 10-Q · filed 2014-11-13 | $2.91M derived: sum of 2 quarters · filed 2015-09-25 | -$6.40M derived: sum of 3 quarters · filed 2015-09-25 | -$6.57M derived: sum of 4 quarters · filed 2015-09-25 | |||||
| 2014-06-30 | $4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-25 | -$4.93M derived: sum of 2 quarters · filed 2015-09-25 | -$5.10M derived: sum of 3 quarters · filed 2015-09-25 | -$5.28M 10-K · filed 2015-09-25 | |||||
| 2014-03-31 | -$9.31M 10-Q · filed 2015-05-14 | -$9.48M derived: sum of 2 quarters · filed 2015-05-14 | -$9.66M 10-Q · filed 2015-05-14 | -$9.80M 10-Q · filed 2014-05-15 | |||||
| 2013-12-31 | -$168.16K 10-Q · filed 2015-02-12 | -$350.22K 10-Q · filed 2015-02-12 | -$490.71K 10-Q · filed 2014-02-05 | ||||||
| 2013-09-30 | -$182.06K 10-Q · filed 2014-11-13 | -$322.56K 10-Q · filed 2013-11-19 | |||||||
| 2013-06-30 | -$140.50K 10-K · filed 2014-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |